A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma
- 12 September 2024
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 205 (5) , 2067-2071
Abstract
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.Keywords
Funding Information
- Roche Canada
- Canadian Cancer Society (704970, 707213)
- Janssen Research and Development
This publication has 9 references indexed in Scilit:
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialThe Lancet, 2022
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaNew England Journal of Medicine, 2022
- A multiprotein supercomplex controlling oncogenic signalling in lymphomaNature, 2018
- A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCLBlood, 2018
- IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDYHematological Oncology, 2017
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNature Medicine, 2015
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12Journal of Clinical Oncology, 2014
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995